As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Cognition Therapeutics, Inc. The largest reported stake is Bios Memory Spv I, LP's, at 6.9%. One filing is on record since September 23, 2025 (Schedule 13D/A, September 23, 2025).
Sell to companies like Cognition Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bios Memory Spv I, LP · Sole voting: 0 · Shared voting: 1,424,014 · Sole dispositive: 0 · Shared dispositive: 1,424,014 · SCHEDULE 13D/A, 2025-09-23
- · Reporting person: Bios Memory Spv Ii, LP · Sole voting: 0 · Shared voting: 385,248 · Sole dispositive: 0 · Shared dispositive: 385,248 · SCHEDULE 13D/A, 2025-09-23
- · Reporting person: Bios Fund I, LP · Sole voting: 0 · Shared voting: 418,926 · Sole dispositive: 0 · Shared dispositive: 418,926 · SCHEDULE 13D/A, 2025-09-23
- · Reporting person: Bios Fund I Qp, LP · Sole voting: 0 · Shared voting: 245,029 · Sole dispositive: 0 · Shared dispositive: 245,029 · SCHEDULE 13D/A, 2025-09-23
- · Reporting person: Bp Directors, LP · Sole voting: 0 · Shared voting: 32,328 · Sole dispositive: 0 · Shared dispositive: 32,328 · SCHEDULE 13D/A, 2025-09-23
Cognition Therapeutics, Inc. has 1 Schedule 13D or 13G filing on record since 2025-09-23. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bios Memory Spv I, LP | 6.9% | 1,424,014 | SCHEDULE 13D/A, 2025-09-23 | 2025-09-19 |
Holding shares or following this stake? See who's behind Cognition Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Watch Cognition Therapeutics, Inc.
Get an email when Cognition Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cognition Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cognition Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cognition Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bios Memory Spv I, LP | 0 | 1,424,014 | 0 | 1,424,014 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Memory Spv Ii, LP | 0 | 385,248 | 0 | 385,248 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund I, LP | 0 | 418,926 | 0 | 418,926 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund I Qp, LP | 0 | 245,029 | 0 | 245,029 | SCHEDULE 13D/A, 2025-09-23 |
| Bp Directors, LP | 0 | 32,328 | 0 | 32,328 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund Ii, LP | 0 | 78,298 | 0 | 78,298 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund Ii Qp, LP | 0 | 255,765 | 0 | 255,765 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund Ii Nt, LP | 0 | 34,238 | 0 | 34,238 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund Iii, LP | 0 | 309,748 | 0 | 309,748 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund Iii Qp, LP | 0 | 2,021,906 | 0 | 2,021,906 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Fund Iii Nt, LP | 0 | 326,733 | 0 | 326,733 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Clinical Opportunity Fund, LP | 0 | 500,095 | 0 | 500,095 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Equity Partners, LP | 0 | 1,081,531 | 0 | 1,081,531 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Equity Partners Ii, LP | 0 | 368,301 | 0 | 368,301 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Equity Partners Iii, LP | 0 | 2,658,387 | 0 | 2,658,387 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Equity Cof, LP | 0 | 500,095 | 0 | 500,095 | SCHEDULE 13D/A, 2025-09-23 |
| Cavu Management, LP | 0 | 5,532,233 | 0 | 5,532,233 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Capital Management, LP | 0 | 6,032,328 | 0 | 6,032,328 | SCHEDULE 13D/A, 2025-09-23 |
| Cavu Advisors, LLC | 0 | 5,532,233 | 0 | 5,532,233 | SCHEDULE 13D/A, 2025-09-23 |
| Bios Advisors Gp, LLC | 0 | 6,032,328 | 0 | 6,032,328 | SCHEDULE 13D/A, 2025-09-23 |
| Leslie W. Kreis | 0 | 5,532,233 | 0 | 5,532,233 | SCHEDULE 13D/A, 2025-09-23 |
| Aaron G.L. Fletcher | 27,227 | 6,032,328 | 27,227 | 6,032,328 | SCHEDULE 13D/A, 2025-09-23 |
The latest filing identifies Cognition Therapeutics, Inc. by CUSIP 19243B102 and gives its principal executive office as 1751 River Run, Suite 400, Fort Worth, TX 76107 (SCHEDULE 13D/A, 2025-09-23).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-23 | Bios Memory Spv I, LP | 6.9% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Cognition Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.